hepatitis B virus infection

Summary

hepatitis B virus infection (MONDO:0005344) is a disease with 21 cohort genes (31 GWAS associations across 17 studies) and 1,160 clinical trials. The dominant Reactome pathway is Interferon gamma signaling (6 cohort genes). Top therapeutic interventions include entecavir anhydrous, tenofovir disoproxil, and tenofovir alafenamide.

At a glance

• Cohort genes: 21
• GWAS associations: 31
• Clinical trials: 1,160

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hepatitis B virus infection
Mondo ID	MONDO:0005344
EFO	EFO:0004197
MeSH	D006509
DOID	DOID:2043
ICD-11	1718385802
NCIT	C3097
SNOMED CT	66071002
UMLS	C0019163
MedGen	6807
Is cancer (heuristic)	no

Also known as: chronic hepatitis B · Hepatitis B · Hepatitis B infection · hepatitis B infection · Hepatitis B virus caused hepatitis · Hepatitis B virus hepatitis · hepatitis type B · viral Hepatitis B

Data availability: 31 GWAS associations (17 studies).

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Hepadnaviridae infectious disease › hepatitis B virus infection

Subtypes (2): chronic hepatitis B virus infection, acute hepatitis B virus infection

Genetics & variants

GWAS landscape

31 GWAS associations across 17 studies. Top hits map to 15 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs3077	2e-61	HLA-DPA1	G	1.87
rs28891489	5e-59	HLA-DQB1 - MTCO3P1	?
rs9277535	3e-54	HLA-DPB1	G	1.77
rs2856718	4e-37	HLA-DQB1 - MTCO3P1	A	1.56
rs7453920	5e-37	HLA-DQB2	G	1.89
rs1419881	1e-18	TCF19	?	1.37
rs2647027	1e-15	HLA-DQB1	G	0.2
rs3130542	9e-14	HCG27 - HLA-C	A	1.33
rs652888	7e-13	EHMT2-AS1, EHMT2	?	1.38
rs4821116	2e-12	UBE2L3	G	1.22
rs7000921	3e-12	LZTS1 - TMEM97P2	C	1.28
rs202090928	6e-12	CACNA1H	G	2.35
rs549882772	1e-11	MAP7	G	2.67
rs571378589	3e-11	EXOG	A	2.63
rs10272859	9e-10	CDK14	G	1.28
rs9277542	2e-09	HLA-DPB1	?
rs11866328	2e-08	GRIN2A	G	1.68
rs615672	1e-06	HLA-DRB1 - HLA-DQA1	?
rs3128923	2e-06	HLA-DPA2 - COL11A2P1	?
rs1537862	2e-06	AFG1L	?
rs421446	3e-06	HSD17B8 - MIR219A1	G	1.47
rs17401966	6e-06	KIF1B	G	1.89

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90651138	Liu TY	2025	9,726	190,942	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90477056	Verma A	2024	2,229	447,136	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST001257	Liu L	2011	1,944	0	A genome-wide association study with DNA pooling identifies the variant rs11866328 in the GRIN2A gene that affects disease progression of chronic HBV infection.
GCST90477055	Verma A	2024	1,940	118,553	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479751	Verma A	2024	1,940	118,553	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST003615	Li Y	2016	1,251	1,057	Genome-wide association study identifies 8p21.3 associated with persistent hepatitis B virus infection among Chinese.
GCST002246	Hu Z	2013	951	0	New loci associated with chronic hepatitis B virus infection in Han Chinese.
GCST012285	Zeng Z	2021	460	0	Genome-wide association study identifies new loci associated with risk of HBV infection and disease progression.
GCST001150	Mbarek H	2011	458	2,056	A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population.
GCST90481435	Verma A	2024	411	59,095	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	4
Tier 3: regulatory	0
Tier 4: intronic/intergenic	17

MAF distribution

Bucket	Variants
common (>=0.05)	19
low_freq (0.01-0.05)	0
rare (<0.01)	3
unknown	0

Functional consequences

Consequence	Count
intergenic_variant	8
intron_variant	7
3_prime_UTR_variant	4
non_coding_transcript_exon_variant	2
missense_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs3077	6	33065245	A>C,G,T	0.4	3_prime_UTR_variant	HLA-DPA1	2e-61	Tier 2: splice/UTR
rs28891489	6	32682585	T>A,C	0.05	intergenic_variant	HLA-DQB1 - MTCO3P1	5e-59	Tier 4: intronic/intergenic
rs9277535	6	33087084	A>G	0.43	3_prime_UTR_variant	HLA-DPB1	3e-54	Tier 2: splice/UTR
rs2856718	6	32702478	C>A,G,T	0.48	intergenic_variant	HLA-DQB1 - MTCO3P1	4e-37	Tier 4: intronic/intergenic
rs7453920	6	32762235	A>G,T	0.13	intron_variant	HLA-DQB2	5e-37	Tier 4: intronic/intergenic
rs1419881	6	31162816	G>A,C,T	0.05	3_prime_UTR_variant	TCF19	1e-18	Tier 2: splice/UTR
rs2647027	6	32667828	G>A,C	0.321	intergenic_variant	HLA-DQB1	1e-15	Tier 4: intronic/intergenic
rs3130542	6	31264334	A>G	0.13	intergenic_variant	HCG27 - HLA-C	9e-14	Tier 4: intronic/intergenic
rs652888	6	31883457	A>C,G,T	0.05	non_coding_transcript_exon_variant	EHMT2-AS1, EHMT2	7e-13	Tier 4: intronic/intergenic
rs4821116	22	21619030	C>A,T	0.41	intron_variant	UBE2L3	2e-12	Tier 4: intronic/intergenic
rs7000921	8	20535695	T>C	0.278	intergenic_variant	LZTS1 - TMEM97P2	3e-12	Tier 4: intronic/intergenic
rs202090928	16	1195441	G>A,C	0	missense_variant	CACNA1H	6e-12	Tier 1: coding
rs549882772	6	136399631	G>A	0	intron_variant	MAP7	1e-11	Tier 4: intronic/intergenic
rs571378589	3	38527485	A>G,T	0	intergenic_variant	EXOG	3e-11	Tier 4: intronic/intergenic
rs10272859	7	90689160	G>A,C	0.313	intron_variant	CDK14	9e-10	Tier 4: intronic/intergenic
rs9277542	6	33087470	T>A,C	0.05	3_prime_UTR_variant	HLA-DPB1	2e-09	Tier 2: splice/UTR
rs11866328	16	9768699	G>A,T	0.05	intron_variant	GRIN2A	2e-08	Tier 4: intronic/intergenic
rs615672	6	32606394	G>A,C	0.05	intergenic_variant	HLA-DRB1 - HLA-DQA1	1e-06	Tier 4: intronic/intergenic
rs3128923	6	33103545	C>A,G	0.05	intergenic_variant	HLA-DPA2 - COL11A2P1	2e-06	Tier 4: intronic/intergenic
rs1537862	6	108368952	T>A,C	0.05	intron_variant	AFG1L	2e-06	Tier 4: intronic/intergenic
rs421446	6	33207006	A>C,G	0.05	non_coding_transcript_exon_variant	HSD17B8 - MIR219A1	3e-06	Tier 4: intronic/intergenic
rs17401966	1	10325413	A>G	0.269	intron_variant	KIF1B	6e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 36 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
UBE2L3	Orphanet:536	Systemic lupus erythematosus
KIF1B	Orphanet:29072	Hereditary pheochromocytoma-paraganglioma
KIF1B	Orphanet:99946	Autosomal dominant Charcot-Marie-Tooth disease type 2A1
CSGALNACT1	Orphanet:1425	Desbuquois syndrome
GRIN2A	Orphanet:163721	Rolandic epilepsy-speech dyspraxia syndrome
GRIN2A	Orphanet:1945	Self-limited epilepsy with centrotemporal spikes
GRIN2A	Orphanet:289266	Early-onset epileptic encephalopathy and intellectual disability due to GRIN2A mutation
GRIN2A	Orphanet:725	Developmental and epileptic encephalopathy with spike-wave activation in sleep
GRIN2A	Orphanet:98818	Landau-Kleffner syndrome
HLA-C	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
HLA-DPA1	Orphanet:900	Granulomatosis with polyangiitis
HLA-DPB1	Orphanet:133	Chronic beryllium disease
HLA-DPB1	Orphanet:900	Granulomatosis with polyangiitis
HLA-DQB1	Orphanet:2073	Narcolepsy type 1
HLA-DQB1	Orphanet:477738	Pediatric multiple sclerosis
HLA-DQB1	Orphanet:703	Bullous pemphigoid
HLA-DQB1	Orphanet:83465	Narcolepsy type 2
HLA-DQB1	Orphanet:930	Idiopathic achalasia
HLA-DRB1	Orphanet:2073	Narcolepsy type 1
HLA-DRB1	Orphanet:220393	Diffuse cutaneous systemic sclerosis
HLA-DRB1	Orphanet:220402	Limited cutaneous systemic sclerosis
HLA-DRB1	Orphanet:220407	Limited systemic sclerosis
HLA-DRB1	Orphanet:3437	Vogt-Koyanagi-Harada disease
HLA-DRB1	Orphanet:397	Giant cell arteritis
HLA-DRB1	Orphanet:477738	Pediatric multiple sclerosis
HLA-DRB1	Orphanet:536	Systemic lupus erythematosus
HLA-DRB1	Orphanet:545	Follicular lymphoma
HLA-DRB1	Orphanet:703	Bullous pemphigoid
HLA-DRB1	Orphanet:747	Autoimmune pulmonary alveolar proteinosis
HLA-DRB1	Orphanet:797	Sarcoidosis
HLA-DRB1	Orphanet:83465	Narcolepsy type 2
HLA-DRB1	Orphanet:85414	Systemic-onset juvenile idiopathic arthritis
LPL	Orphanet:309015	Familial lipoprotein lipase deficiency
ATP6V1B2	Orphanet:3473	Zimmermann-Laband syndrome
ATP6V1B2	Orphanet:79499	Autosomal dominant deafness-onychodystrophy syndrome
ATP6V1B2	Orphanet:79500	DOORS syndrome

Cohort genes → proteins

21 cohort genes, 19 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	21

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SLC18A1	HGNC:10934	ENSG00000036565	P54219	Chromaffin granule amine transporter	gwas
TCF19	HGNC:11629	ENSG00000137310	Q9Y242	Transcription factor 19	gwas
UBE2L3	HGNC:12488	ENSG00000185651	P68036	Ubiquitin-conjugating enzyme E2 L3	gwas
LZTS1	HGNC:13861	ENSG00000061337	Q9Y250	Leucine zipper putative tumor suppressor 1	gwas
EHMT2	HGNC:14129	ENSG00000204371	Q96KQ7	Histone-lysine N-methyltransferase EHMT2	gwas
AFG1L	HGNC:16411	ENSG00000135537	Q8WV93	AFG1-like ATPase	gwas
KIF1B	HGNC:16636	ENSG00000054523	O60333	Kinesin-like protein KIF1B	gwas
CSGALNACT1	HGNC:24290	ENSG00000147408	Q8TDX6	Chondroitin sulfate N-acetylgalactosaminyltransferase 1	gwas
INTS10	HGNC:25548	ENSG00000104613	Q9NVR2	Integrator complex subunit 10	gwas
MIR219A1	HGNC:31597	ENSG00000199036		microRNA 219a-1	gwas
GRIN2A	HGNC:4585	ENSG00000183454	Q12879	Glutamate receptor ionotropic, NMDA 2A	gwas
HLA-C	HGNC:4933	ENSG00000204525	P10321	HLA class I histocompatibility antigen, C alpha chain	gwas
HLA-DPA1	HGNC:4938	ENSG00000231389	P20036	HLA class II histocompatibility antigen, DP alpha 1 chain	gwas
HLA-DPA2	HGNC:4939	ENSG00000231461		major histocompatibility complex, class II, DP alpha 2 (pseudogene)	gwas
HLA-DPB1	HGNC:4940	ENSG00000223865	P04440	HLA class II histocompatibility antigen, DP beta 1 chain	gwas
HLA-DQB1	HGNC:4944	ENSG00000179344	P01920	HLA class II histocompatibility antigen, DQ beta 1 chain	gwas
HLA-DQB2	HGNC:4945	ENSG00000232629	P05538	HLA class II histocompatibility antigen, DQ beta 2 chain	gwas
HLA-DRB1	HGNC:4948	ENSG00000196126	P01911	HLA class II histocompatibility antigen, DRB1 beta chain	gwas
LPL	HGNC:6677	ENSG00000175445	P06858	Lipoprotein lipase	gwas
ATP6V1B2	HGNC:854	ENSG00000147416	P21281	V-type proton ATPase subunit B, brain isoform	gwas
CDK14	HGNC:8883	ENSG00000058091	O94921	Cyclin-dependent kinase 14	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SLC18A1	Chromaffin granule amine transporter	Electrogenic antiporter that exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles.
TCF19	Transcription factor 19	Potential transcription factor that may play a role in the regulation of genes involved in cell cycle G1/S transition.
UBE2L3	Ubiquitin-conjugating enzyme E2 L3	Ubiquitin-conjugating enzyme E2 that specifically acts with HECT-type and RBR family E3 ubiquitin-protein ligases.
LZTS1	Leucine zipper putative tumor suppressor 1	Involved in the regulation of cell growth.
EHMT2	Histone-lysine N-methyltransferase EHMT2	Histone methyltransferase that specifically mono- and dimethylates ‘Lys-9’ of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin.
AFG1L	AFG1-like ATPase	Putative mitochondrial ATPase.
KIF1B	Kinesin-like protein KIF1B	Has a plus-end-directed microtubule motor activity and functions as a motor for transport of vesicles and organelles along microtubules.
CSGALNACT1	Chondroitin sulfate N-acetylgalactosaminyltransferase 1	Transfers 1,4-N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of glucuronic acid (GlcUA).
INTS10	Integrator complex subunit 10	Component of the integrator complex, a multiprotein complex that terminates RNA polymerase II (Pol II) transcription in the promoter-proximal region of genes.
GRIN2A	Glutamate receptor ionotropic, NMDA 2A	Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+).
HLA-C	HLA class I histocompatibility antigen, C alpha chain	Antigen-presenting major histocompatibility complex class I (MHCI) molecule with an important role in reproduction and antiviral immunity.
HLA-DPA1	HLA class II histocompatibility antigen, DP alpha 1 chain	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells.
HLA-DPB1	HLA class II histocompatibility antigen, DP beta 1 chain	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells.
HLA-DQB1	HLA class II histocompatibility antigen, DQ beta 1 chain	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells.
HLA-DQB2	HLA class II histocompatibility antigen, DQ beta 2 chain	Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells.
HLA-DRB1	HLA class II histocompatibility antigen, DRB1 beta chain	A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule.
LPL	Lipoprotein lipase	Key enzyme in triglyceride metabolism.
ATP6V1B2	V-type proton ATPase subunit B, brain isoform	Non-catalytic subunit of the V1 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons.
CDK14	Cyclin-dependent kinase 14	Serine/threonine-protein kinase involved in the control of the eukaryotic cell cycle, whose activity is controlled by an associated cyclin.

Protein-family classification

Druggable: 11 · Difficult: 3 · Unknown: 7 · Druggable fraction: 0.52

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Antibody/Immunoglobulin	6	8.3×	4e-04
Transporter	1	3.7×	0.591
Enzyme (other)	3	1.7×	0.591
Scaffold/PPI	2	1.6×	0.604
Kinase	1	1.3×	0.753
Other/Unknown	7	0.6×	0.989
Transcription factor	1	0.4×	0.989

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SLC18A1	Transporter	yes		Tet-R_TetA/multi-R_MdtG-like, MFS, MFS_dom
TCF19	Transcription factor	no		FHA_dom, Znf_PHD, SMAD_FHA_dom_sf
UBE2L3	Enzyme (other)	yes	2.3.2.23	UBC, UBQ-conjugating_enzyme/RWD, UBQ-conjugating_AS
LZTS1	Other/Unknown	no		LZTS
EHMT2	Scaffold/PPI	no	2.1.1.355	SET_dom, Ankyrin_rpt, Pre-SET_dom
AFG1L	Other/Unknown	no		ATPase_AFG1-like, P-loop_NTPase
KIF1B	Scaffold/PPI	no		FHA_dom, Kinesin_motor_dom, PH_domain
CSGALNACT1	Enzyme (other)	yes	2.4.1.174	Chond_GalNAc, Nucleotide-diphossugar_trans, CS_glycosyltransferase
INTS10	Other/Unknown	no		Int_cplx_su10
MIR219A1	Other/Unknown	no
GRIN2A	Other/Unknown	no		Iontro_rcpt_C, Iono_Glu_rcpt_met, ANF_lig-bd_rcpt
HLA-C	Antibody/Immunoglobulin	yes		MHC_I_a_a1/a2, Ig_C1-set, Ig-like_dom
HLA-DPA1	Antibody/Immunoglobulin	yes		MHC_II_a_N, Ig/MHC_CS, Ig_C1-set
HLA-DPA2	Other/Unknown	no
HLA-DPB1	Antibody/Immunoglobulin	yes		MHC_II_b_N, Ig/MHC_CS, Ig_C1-set
HLA-DQB1	Antibody/Immunoglobulin	yes		MHC_II_b_N, Ig/MHC_CS, Ig_C1-set
HLA-DQB2	Antibody/Immunoglobulin	yes		MHC_II_b_N, Ig/MHC_CS, Ig_C1-set
HLA-DRB1	Antibody/Immunoglobulin	yes		MHC_II_b_N, Ig/MHC_CS, Ig_C1-set
LPL	Enzyme (other)	yes	3.1.1.34	TAG_lipase, PLAT/LH2_dom, Lipo_Lipase
ATP6V1B2	Other/Unknown	no		ATPase_F1/V1/A1_a/bsu_nucl-bd, ATPase_F1/V1/A1_a/bsu_N, ATPase_V1-cplx_bsu
CDK14	Kinase	yes		Prot_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf

Expression context

Cohort genes with no expression data: 0.

17 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	21
unknown	0

Top tissues across cohort

Tissue	Cohort genes
granulocyte	6
lymph node	3
right lung	3
male germ line stem cell (sensu Vertebrata) in testis	2
ganglionic eminence	2
nucleus accumbens	2
spleen	2
monocyte	2
vermiform appendix	2
buccal mucosa cell	1
diaphragm	1
primordial germ cell in gonad	1
ventricular zone	1
mucosa of transverse colon	1
oocyte	1
secondary oocyte	1
cortical plate	1
putamen	1
left testis	1
right testis	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SLC18A1	79	tissue_specific	marker	diaphragm, male germ line stem cell (sensu Vertebrata) in testis, buccal mucosa cell
TCF19	133	ubiquitous	yes	primordial germ cell in gonad, ventricular zone, lymph node
UBE2L3	287	ubiquitous	marker	oocyte, secondary oocyte, mucosa of transverse colon
LZTS1	200	broad	marker	cortical plate, ganglionic eminence, nucleus accumbens
EHMT2	134	ubiquitous	marker	nucleus accumbens, ganglionic eminence, putamen
AFG1L	164	ubiquitous	yes	left testis, right testis, male germ line stem cell (sensu Vertebrata) in testis
KIF1B	287	ubiquitous	marker	skeletal muscle tissue of rectus abdominis, biceps brachii, medial globus pallidus
CSGALNACT1	280	broad	marker	cartilage tissue, cardiac muscle of right atrium, synovial joint
INTS10	261	ubiquitous	marker	body of pancreas, right uterine tube, cerebellar hemisphere
MIR219A1	107		yes	sural nerve, granulocyte, olfactory segment of nasal mucosa
GRIN2A	199	broad	marker	Brodmann (1909) area 23, endothelial cell, middle temporal gyrus
HLA-C	134	ubiquitous	marker	blood, right lung, spleen
HLA-DPA1	133	ubiquitous	marker	monocyte, leukocyte, granulocyte
HLA-DPA2	28		yes	granulocyte, cerebellar cortex, cerebellum
HLA-DPB1	135	ubiquitous	marker	granulocyte, lymph node, vermiform appendix
HLA-DQB1	268	broad	marker	right lung, spleen, upper lobe of left lung
HLA-DQB2	127	tissue_specific	marker	lymph node, granulocyte, skin of abdomen
HLA-DRB1	131	tissue_specific	marker	vermiform appendix, granulocyte, right lung
LPL	272	broad	marker	olfactory bulb, trigeminal ganglion, dorsal root ganglion
ATP6V1B2	300	ubiquitous	marker	pons, monocyte, lateral nuclear group of thalamus
CDK14	279	ubiquitous	marker	postcentral gyrus, parietal lobe, CA1 field of hippocampus

Protein interactions among cohort

Intra-cohort edges: 6.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
EHMT2	4,723
HLA-DRB1	3,448
GRIN2A	3,146
CDK14	3,135
ATP6V1B2	2,898
KIF1B	2,257
LPL	2,149
TCF19	1,774
HLA-DQB2	1,547
LZTS1	1,230

Intra-cohort edges

A	B	Sources
EHMT2	TCF19	string_interaction
HLA-C	HLA-DQB1	intact
HLA-DPA1	HLA-DPB1	intact
HLA-DPA1	HLA-DQB1	intact
HLA-DQB2	TCF19	string_interaction
INTS10	TCF19	string_interaction

Structural data

PDB: 14 · AlphaFold-only: 5 · No structure: 2

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
HLA-DRB1	P01911	108
GRIN2A	Q12879	37
EHMT2	Q96KQ7	35
UBE2L3	P68036	21
HLA-C	P10321	13
HLA-DPA1	P20036	10
HLA-DPB1	P04440	10
HLA-DQB1	P01920	10
SLC18A1	P54219	8
INTS10	Q9NVR2	8
ATP6V1B2	P21281	8
LPL	P06858	5
LZTS1	Q9Y250	1
KIF1B	O60333	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
CSGALNACT1	Q8TDX6	87.71
HLA-DQB2	P05538	86.87
AFG1L	Q8WV93	78.92
CDK14	O94921	71.10
TCF19	Q9Y242	63.17

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 74. Enrichment computed across 21 evidence-associated genes (15 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 15 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Interferon gamma signaling	6	50.2×	8e-08	HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DQB2, HLA-DRB1
Translocation of ZAP-70 to Immunological synapse	4	169.2×	2e-07	HLA-DPA1, HLA-DPB1, HLA-DQB2, HLA-DRB1
Phosphorylation of CD3 and TCR zeta chains	4	145.0×	3e-07	HLA-DPA1, HLA-DPB1, HLA-DQB2, HLA-DRB1
Co-inhibition by PD-1	4	138.4×	3e-07	HLA-DPA1, HLA-DPB1, HLA-DQB2, HLA-DRB1
Generation of second messenger molecules	4	92.3×	1e-06	HLA-DPA1, HLA-DPB1, HLA-DQB2, HLA-DRB1
Downstream TCR signaling	4	34.2×	5e-05	HLA-DPA1, HLA-DPB1, HLA-DQB2, HLA-DRB1
MHC class II antigen presentation	4	23.8×	2e-04	HLA-DPA1, HLA-DPB1, HLA-DQB2, HLA-DRB1
Chylomicron remodeling	1	76.1×	0.113	LPL
Endosomal/Vacuolar pathway	1	69.2×	0.113	HLA-C
Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy	1	44.8×	0.113	ATP6V1B2
Assembly of active LPL and LIPC lipase complexes	1	40.1×	0.113	LPL
MECP2 regulates neuronal receptors and channels	1	40.1×	0.113	GRIN2A
CS-GAG biosynthesis	1	36.2×	0.113	CSGALNACT1
Unblocking of NMDA receptors, glutamate binding and activation	1	36.2×	0.113	GRIN2A
Regulation of TP53 Activity through Methylation	1	36.2×	0.113	EHMT2
Synaptic adhesion-like molecules	1	36.2×	0.113	GRIN2A
Negative regulation of NMDA receptor-mediated neuronal transmission	1	36.2×	0.113	GRIN2A
DAP12 interactions	1	31.7×	0.113	HLA-C
Plasma lipoprotein remodeling	1	31.7×	0.113	LPL
Long-term potentiation	1	31.7×	0.113	GRIN2A
Regulation of necroptotic cell death	1	29.3×	0.113	UBE2L3
Antigen Presentation: Folding, assembly and peptide loading of class I MHC	1	26.2×	0.113	HLA-C
Metabolism of fat-soluble vitamins	1	25.4×	0.113	LPL
Insulin receptor recycling	1	25.4×	0.113	ATP6V1B2
Synthesis of active ubiquitin: roles of E1 and E2 enzymes	1	24.6×	0.113	UBE2L3
Transferrin endocytosis and recycling	1	24.6×	0.113	ATP6V1B2
PINK1-PRKN Mediated Mitophagy	1	23.8×	0.113	UBE2L3
ROS and RNS production in phagocytes	1	22.4×	0.116	ATP6V1B2
Transcriptional Regulation by E2F6	1	19.5×	0.128	EHMT2
Transcriptional Regulation by VENTX	1	17.7×	0.132	EHMT2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 19 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
peptide antigen assembly with MHC class II protein complex	5	277.2×	8e-10	HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DQB2, HLA-DRB1
antigen processing and presentation of exogenous peptide antigen via MHC class II	5	143.1×	1e-08	HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DQB2, HLA-DRB1
positive regulation of immune response	5	126.7×	2e-08	HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DQB2, HLA-DRB1
positive regulation of T cell activation	5	116.7×	2e-08	HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DQB2, HLA-DRB1
adaptive immune response	5	22.2×	8e-05	HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DQB2
immune response	5	12.4×	0.001	HLA-C, HLA-DPA1, HLA-DQB1, HLA-DQB2, HLA-DRB1
T cell receptor signaling pathway	3	24.0×	0.006	HLA-DPB1, HLA-DQB1, HLA-DRB1
positive regulation of T cell mediated cytotoxicity	2	53.8×	0.014	HLA-C, HLA-DRB1
regulation of interleukin-4 production	1	887.0×	0.018	HLA-DRB1
phenotypic switching	1	887.0×	0.018	EHMT2
UDP-glucuronate metabolic process	1	887.0×	0.018	CSGALNACT1
antigen processing and presentation of endogenous peptide antigen via MHC class II	1	443.5×	0.026	HLA-DRB1
regulation of interleukin-10 production	1	443.5×	0.026	HLA-DRB1
humoral immune response	2	29.6×	0.026	HLA-DQB1, HLA-DRB1
positive regulation of T cell proliferation	2	27.3×	0.026	HLA-DPA1, HLA-DPB1
regulation of synaptic plasticity	2	27.3×	0.026	LZTS1, GRIN2A
myeloid dendritic cell antigen processing and presentation	1	295.6×	0.027	HLA-DRB1
aminergic neurotransmitter loading into synaptic vesicle	1	295.6×	0.027	SLC18A1
directional locomotion	1	295.6×	0.027	GRIN2A
low-density lipoprotein particle mediated signaling	1	295.6×	0.027	LPL
protein localization to postsynaptic membrane	1	295.6×	0.027	GRIN2A
positive regulation of type II interferon production	2	23.6×	0.027	HLA-DPA1, HLA-DPB1
UDP-N-acetylgalactosamine metabolic process	1	221.7×	0.029	CSGALNACT1
chylomicron remodeling	1	221.7×	0.029	LPL
regulation of T-helper cell differentiation	1	221.7×	0.029	HLA-DRB1
mitochondrial protein quality control	1	221.7×	0.029	AFG1L
positive regulation of CD4-positive, alpha-beta T cell activation	1	221.7×	0.029	HLA-DRB1
peptidyl-lysine dimethylation	1	177.4×	0.032	EHMT2
positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation	1	177.4×	0.032	HLA-DRB1
very-low-density lipoprotein particle clearance	1	177.4×	0.032	LPL

Therapeutics

Drugs indicated for this disease

8 approved, 9 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Adefovir Dipivoxil	Approved (phase 4)
HEPATITIS B VIRUS S PROTEIN, PRE-S1 PROTEIN AND PRE-S2 PROTEIN VIRUS LIKE PARTICLES	Approved (phase 4)
Hepatitis B Immune Globulin	Approved (phase 4)
Hepatitis B Virus Hbsag Surface Protein Antigen	Approved (phase 4)
INTERFERON ALFA-2B	Approved (phase 4)
Lamivudine	Approved (phase 4)
PEGINTERFERON ALFA-2A	Approved (phase 4)
Telbivudine	Approved (phase 4)
Adefovir	Phase 3 (in late-stage trials)
Bepirovirsen	Phase 3 (in late-stage trials)
Clevudine	Phase 3 (in late-stage trials)
Emtricitabine	Phase 3 (in late-stage trials)
Hepatitis B Virus Vaccine Inactivated	Phase 3 (in late-stage trials)
Ribavirin	Phase 3 (in late-stage trials)
Tenofovir Alafenamide	Phase 3 (in late-stage trials)
Tenofovir Anhydrous	Phase 3 (in late-stage trials)
Thimerosal	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): 1018 ISS, Bulevirtide, Daclatasvir, Dasabuvir, Imiquimod, Ledipasvir, Nivolumab, Ombitasvir, PEGINTERFERON LAMBDA-1A, Paritaprevir, Ritonavir, Sodium Chloride, Sofosbuvir, Tenofovir Disoproxil, Terfenadine.

Drug target analysis

Approved (phase 4): 6 · Phase ≥3: 6 · Phased (≥1): 6 · Undrugged: 15

Druggability breadth: 11 of 21 evidence-associated genes (52%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
SLC18A1	RESERPINE
EHMT2	RALTITREXED
GRIN2A	MEMANTINE HYDROCHLORIDE
LPL	ORLISTAT
ATP6V1B2	ENOXACIN
CDK14	FEDRATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
GRIN2A	37	4
CDK14	17	4
EHMT2	7	4
SLC18A1	1	4
LPL	1	4
ATP6V1B2	1	4
TCF19	0	0
UBE2L3	0	0
LZTS1	0	0
AFG1L	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
RESERPINE	4	SLC18A1
RALTITREXED	4	EHMT2
TAZEMETOSTAT	4	EHMT2
DISULFIRAM	4	EHMT2
MEMANTINE HYDROCHLORIDE	4	GRIN2A
ESKETAMINE	4	GRIN2A
DEXTROMETHORPHAN	4	GRIN2A
PENTAMIDINE	4	GRIN2A
AMANTADINE	4	GRIN2A
KETAMINE	4	GRIN2A
CYCLOSERINE	4	GRIN2A
MEMANTINE	4	GRIN2A
TACRINE	4	GRIN2A
LEVORPHANOL	4	GRIN2A
CHLORPROMAZINE	4	GRIN2A
PROCYCLIDINE	4	GRIN2A
ORPHENADRINE	4	GRIN2A
ORLISTAT	4	LPL
ENOXACIN	4	ATP6V1B2
FEDRATINIB	4	CDK14
SORAFENIB	4	CDK14
BOSUTINIB	4	CDK14
NINTEDANIB	4	CDK14
SUNITINIB	4	CDK14
EBSELEN	3	EHMT2
ESMETHADONE	3	GRIN2A
DALZANEMDOR	3	GRIN2A
LATREPIRDINE	3	GRIN2A
GLUTAMIC ACID	3	GRIN2A
ENZASTAURIN	3	CDK14

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 4.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
EHMT2	442	Binding:435, Functional:6, ADMET:1
GRIN2A	324	Binding:296, Functional:23, ADMET:4, Toxicity:1
CDK14	179	Binding:179
HLA-DRB1	17	Binding:17
LPL	16	Binding:16
CSGALNACT1	9	Binding:9
ATP6V1B2	3	Binding:3
SLC18A1	2	Functional:1, Binding:1
UBE2L3	2	Binding:2
KIF1B	1	Binding:1
HLA-C	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
UBE2L3	2.3.2.23, 2.3.2.24	E2 ubiquitin-conjugating enzyme, (E3-independent) E2 ubiquitin-conjugating enzyme
EHMT2	2.1.1.355, 2.1.1.356, 2.1.1.367, 2.1.1.368	[histone H3]-lysine9 N-trimethyltransferase, [histone H3]-lysine27 N-trimethyltransferase, [histone H3]-lysine9 N-methyltransferase, [histone H3]-lysine9 N-dimethyltransferase
CSGALNACT1	2.4.1.174, 2.4.1.175	glucuronylgalactosylproteoglycan 4-beta-N-acetylgalactosaminyltransferase, glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase
LPL	3.1.1.34	lipoprotein lipase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
EHMT2	442
GRIN2A	324
CDK14	179

Pharmacogenomics

Cohort genes with a PharmGKB record: 21; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
RESERPINE	4	SLC18A1
RALTITREXED	4	EHMT2
TAZEMETOSTAT	4	EHMT2
DISULFIRAM	4	EHMT2
MEMANTINE HYDROCHLORIDE	4	GRIN2A
ESKETAMINE	4	GRIN2A
DEXTROMETHORPHAN	4	GRIN2A
PENTAMIDINE	4	GRIN2A
AMANTADINE	4	GRIN2A
KETAMINE	4	GRIN2A
CYCLOSERINE	4	GRIN2A
MEMANTINE	4	GRIN2A
TACRINE	4	GRIN2A
LEVORPHANOL	4	GRIN2A
CHLORPROMAZINE	4	GRIN2A
PROCYCLIDINE	4	GRIN2A
ORPHENADRINE	4	GRIN2A
ORLISTAT	4	LPL
ENOXACIN	4	ATP6V1B2
FEDRATINIB	4	CDK14
SORAFENIB	4	CDK14
BOSUTINIB	4	CDK14
NINTEDANIB	4	CDK14
SUNITINIB	4	CDK14
EBSELEN	3	EHMT2
ESMETHADONE	3	GRIN2A
DALZANEMDOR	3	GRIN2A
LATREPIRDINE	3	GRIN2A
GLUTAMIC ACID	3	GRIN2A
ENZASTAURIN	3	CDK14

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	6	SLC18A1, EHMT2, GRIN2A, LPL, ATP6V1B2, CDK14
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	6	UBE2L3, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DRB1
D	Druggable family + AlphaFold only, no drug	2	CSGALNACT1, HLA-DQB2
E	Difficult family or no structure, no drug	7	TCF19, LZTS1, AFG1L, KIF1B, INTS10, MIR219A1, HLA-DPA2

Undrugged target profiles

15 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
TCF19	0	—
UBE2L3	2	—
LZTS1	0	—
AFG1L	0	—
KIF1B	1	—
CSGALNACT1	9	—
INTS10	0	—
MIR219A1	0	—
HLA-C	1	—
HLA-DPA1	0	—
HLA-DPA2	0	—
HLA-DPB1	0	—
HLA-DQB1	0	—
HLA-DQB2	0	—
HLA-DRB1	17	—

Clinical trials & evidence

Clinical trials

Clinical trials: 1,160.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	361
PHASE4	224
PHASE3	181
PHASE2	165
PHASE1	123
PHASE1/PHASE2	27
PHASE2/PHASE3	14
EARLY_PHASE1	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02779465	PHASE4	NOT_YET_RECRUITING	Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma
NCT03753074	PHASE4	ACTIVE_NOT_RECRUITING	Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines
NCT03792919	PHASE4	RECRUITING	Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)
NCT03933384	PHASE4	RECRUITING	Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
NCT04496882	PHASE4	ACTIVE_NOT_RECRUITING	Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
NCT04588077	PHASE4	RECRUITING	Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
NCT05147090	PHASE4	ACTIVE_NOT_RECRUITING	Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
NCT05410496	PHASE4	ACTIVE_NOT_RECRUITING	Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection
NCT05853718	PHASE4	RECRUITING	Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women
NCT06084234	PHASE4	RECRUITING	National Liver Cancer Screening Trial
NCT06364930	PHASE4	RECRUITING	SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus
NCT06368882	PHASE4	RECRUITING	Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）
NCT06786429	PHASE4	NOT_YET_RECRUITING	Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
NCT06900166	PHASE4	NOT_YET_RECRUITING	Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg
NCT07071636	PHASE4	NOT_YET_RECRUITING	Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients
NCT07258251	PHASE4	NOT_YET_RECRUITING	Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach
NCT07345611	PHASE4	NOT_YET_RECRUITING	Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B
NCT07345624	PHASE4	NOT_YET_RECRUITING	Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B
NCT07573943	PHASE4	RECRUITING	ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
NCT00106964	PHASE4	COMPLETED	Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
NCT00117533	PHASE4	UNKNOWN	Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
NCT00127959	PHASE4	COMPLETED	Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection
NCT00169858	PHASE4	COMPLETED	Long Term Immunogenicity Study of Engerix-B Vaccine in 10 Year Old Children and the Effect of Booster Injections
NCT00186836	PHASE4	COMPLETED	Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients
NCT00197158	PHASE4	COMPLETED	Comparison of Monodose and Multidose Presentations of GSK Biologicals’ Hepatitis B Vaccine in Terms of Immune Response
NCT00222664	PHASE4	COMPLETED	Qidong Hepatitis B Intervention Study
NCT00226382	PHASE4	COMPLETED	Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment
NCT00230061	PHASE4	COMPLETED	Hepatitis B Vaccination in HIV-infected Persons
NCT00230477	PHASE4	COMPLETED	Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT
NCT00240500	PHASE4	COMPLETED	Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers
NCT00240526	PHASE4	COMPLETED	LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers
NCT00240539	PHASE4	COMPLETED	Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg)
NCT00289731	PHASE4	COMPLETED	Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc
NCT00291616	PHASE4	COMPLETED	Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B
NCT00307242	PHASE4	COMPLETED	Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B
NCT00324961	PHASE4	COMPLETED	Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B
NCT00329576	PHASE4	COMPLETED	Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine
NCT00335881	PHASE4	COMPLETED	Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
NCT00338780	PHASE4	COMPLETED	Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)
NCT00347009	PHASE4	COMPLETED	Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ENTECAVIR ANHYDROUS	4	141
TENOFOVIR DISOPROXIL	4	61
TENOFOVIR ALAFENAMIDE	4	59
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN	4	36
TELBIVUDINE	4	30
ADEFOVIR DIPIVOXIL	4	24
PEGINTERFERON ALFA-2A	4	17
LAMIVUDINE	4	12
PEGINTERFERON ALFA-2B	4	7
STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197	4	5
TERFENADINE	4	5
EMTRICITABINE	4	4
HEPATITIS B IMMUNE GLOBULIN	4	3
ROTAVIRUS, LIVE ATTENUATED	4	3
ZIDOVUDINE	4	2
ABACAVIR	4	1
ALBUMIN HUMAN	4	1
ALDESLEUKIN	4	1
BULEVIRTIDE	4	1
CARBAMAZEPINE	4	1
DIPHENHYDRAMINE	4	1
EFAVIRENZ	4	1
EMPAGLIFLOZIN	4	1
ETHINYL ESTRADIOL	4	1
ETRAVIRINE	4	1
HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES	4	1
IBRUTINIB	4	1
IMIQUIMOD	4	1
INTERFERON ALFA-2A	4	1
LEDIPASVIR	4	1